Skip to main content
Clinic Retatrutide

An editorial reading desk for the triple-agonist clinical record — Phase 2, TRIUMPH Phase 3, and what the trials actually measured.

Retatrutide References: Studies Behind the Numbers

This page lists every Retatrutide source in citation order. Each numbered link opens a public study record or paper when available. This site didn't run the studies. The links let you compare a claim with the researchers' report. Dates show what was public when we checked.

  1. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. ↗
  2. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. ↗
  3. Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(8):2195-2204. ↗
  4. Li et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discov. 2024;10:76. ↗
  5. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1 topline results). Eli Lilly Investor Relations / PR Newswire. 2025. ↗
  6. Coskun T, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025. ↗
  7. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. PMC / systematic review. 2025. ↗
  8. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial. Eli Lilly Investor Relations. 2025. ↗
  9. Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials. PubMed. 2024. ↗
  10. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. PMC. 2025. ↗
  11. Clinical Trials Arena / ESC Congress presentation. ESC 2024: Retatrutide improves lipid and cardiovascular risk profile in Phase II trial. Clinical Trials Arena. 2024. ↗
  12. Pasqualotto E, et al. Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials. Metabolism Open. 2024. ↗
  13. Belay KE, Jemal RH, Tuyizere A. Innovative Glucagon-based Therapies for Obesity. J Endocr Soc. 2024;8(12). ↗
  14. Lopes T, Hope DCD, Ramos-Pittol JM, et al. Dietary protein defends lean mass and maintains the metabolic benefits of glucagon receptor agonism in mice. Mol Metab. 2024;89:102024. ↗
  15. Alves GAM, Teranishi M, Ortega ACTCG, James F, Arachchige ASPM. Mechanisms of GLP-1 in Modulating Craving and Addiction: Neurobiological and Translational Insights. Med Sci (Basel). 2025;13(3):136. ↗
  16. Goldney J, Hamza M, Surti F, Davies MJ, Papamargaritis D. Triple Agonism Based Therapies for Obesity. Curr Cardiovasc Risk Rep. 2025. ↗
  17. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. PR Newswire. 2025. ↗
  18. Weight Regain After GLP-1-Based Therapy Discontinuation: Failure, Physiology, or Follow-Up Gap. PubMed. 2025. ↗
  19. Ramsbacher N. The First Triple Agonist for Antiobesity: Retatrutide. Clin Diabetes. 2024;42(4):499-507. ↗
  20. Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide — A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15(6):796. ↗
  21. Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, Benson CT, Hernandez-Illas M, D'Alessio DA, Milicevic Z. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400:1869-1881. ↗
  22. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist: a systematic review and meta-analysis. Proc (Bayl Univ Med Cent). 2025. ↗